Peter Zerhouni joined Affibody as Chief Business Officer (CBO) in April of 2023. He will combine the roles of CFO and CBO.

“Since joining Affibody, I have been thoroughly impressed with my colleagues’ expertise and the potential of the product pipeline. I am excited to contribute to our strategic growth initiatives and taking the Company to the next level,” said Peter Zerhouni, CFO and CBO of Affibody.

Peter Zerhouni has vast experience from leading positions in biopharmaceutical companies. As CEO of InDex Pharmaceuticals he was responsible for taking the company public and raising more than USD 100 million in financings. He also led the clinical development of InDex’s lead asset through Phase 2 and into Phase 3, as well as preparing for commercialization and launch. Prior to this he was with Diamyd Medical, both as President and CEO and Director of Business Development. During his time at Diamyd he was responsible for leading the business development efforts that led to a USD 625 million partnership with Johnson & Johnson. Earlier in his career he worked at the global financial institution ING Group.

Peter Zerhouni holds an MSc in Biology and a BSc in Business Administration and Economics from Lund University, and he has also studied at University of California at Berkeley.